Evaluation of exercise on individuals with dementia and their carers: a randomised controlled trial by Cerga-Pashoja, Arlinda et al.
TRIALS
Cerga-Pashoja et al. Trials 2010, 11:53
http://www.trialsjournal.com/content/11/1/53
Open Access STUDY PROTOCOL
BioMed  Central
© 2010 Cerga-Pashoja et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Study protocol Evaluation of exercise on individuals with 
dementia and their carers: a randomised controlled 
trial
Arlinda Cerga-Pashoja1,2, David Lowery1,2, Rahul Bhattacharya3, Mark Griffin2, Steve Iliffe2, James Lee4, Claire Leonard5, 
Sue Ricketts4, Lyn Strother6, Fiona Waters1, Craig W Ritchie7 and James Warner*1,7
Abstract
Background: Almost all of the 820,000 people in the UK with dementia will experience Behavioural and Psychological 
Symptoms of Dementia (BPSD). However, research has traditionally focused on treating cognitive symptoms, thus 
neglecting core clinical symptoms that often have a more profound impact on living with dementia. Recent evidence 
(Kales et al, 2007; Ballard et al, 2009) indicates that the popular approach to managing BPSD - prescription of anti-
psychotic medication - can increase mortality and the risk of stroke in people with dementia as well as impair quality of 
life and accelerate cognitive decline. Consequently, there is a need to evaluate the impact that non-pharmacological 
interventions have on BPSD; we believe physical exercise is a particularly promising approach.
Methods/Design: We will carry out a pragmatic, randomised, single-blind controlled trial to evaluate the effectiveness 
of exercise (planned walking) on the behavioural and psychological symptoms of individuals with dementia. We aim to 
recruit 146 people with dementia and their carers to be randomized into two groups; one will be trained in a 
structured, tailored walking programme, while the other will continue with treatment as usual. The primary outcome 
(BPSD) will be assessed with the Neuropsychiatric Inventory (NPI) along with relevant secondary outcomes at baseline, 
6 and 12 weeks.
Discussion: Designing this study has been challenging both ethically and methodologically. In particular to design an 
intervention that is simple, measurable, safe, non-invasive and enjoyable has been testing and has required a lot of 
thought. Throughout the design, we have attempted to balance methodological rigour with study feasibility. We will 
discuss the challenges that were faced and overcome in this paper.
Trial Registration: ISRCTN01423159
Background
"Country air, moderate exercise, and a tonic regimen
may retard the progress of senile dementia and sus-
pend to some extent its termination[1]". J.E.D. Esqui-
rol, 1845
Dementia is a degenerative disease of the brain that
leads to impairment of memory and global intellectual
deterioration without affecting consciousness [2]. The
prevalence rises sharply with increasing age: 5% of those
over 65 and 20% for those aged over 80 will have demen-
tia [3]. Dementia is also associated with a cluster of non-
cognitive symptoms and behaviours that are an integral
part of the syndrome. Commonly described as Behav-
ioural and Psychological Symptoms of Dementia (BPSD),
they include disturbed perception, thought content,
mood or behaviour that frequently occur in patients with
dementia [4]. Although recognised as core to the phe-
nomenology of dementia in Alzheimer's seminal case
studies [5], these symptoms have received relatively little
attention from the research community. This is surpris-
ing given that upwards of 80% of people with dementia
will experience BPSD at some point during the course of
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their illness [6]. Apart from the obvious distress for the
person, BPSD are commonly associated with reduction in
the quality of life for the person as well as their caregivers
[7]; increase of caregiver stress [8], costs of care [9]; and
unsurprisingly premature institutionalization [10].
Although there is some evidence supporting the treat-
ment of BPSD with antipsychotics, there have been
increasing concerns over the safety of these drugs for
people with dementia. Two recent studies indicate that
there is a long-term risk of mortality in patients with
dementia who take antipsychotic medication [11,12].
Non pharmacological alternatives that have been
reported to have a positive effects include music therapy,
bright light therapy, behavioural interventions and exer-
cise[13]. As well as the potential improvement in physical
well being exercise has been demonstrated to have a posi-
tive effect on cognitive symptoms and mood [14,15].
Interventions such as exercise may offer a safer effective
alternative to pharmacological treatments and could also
be empowering to individuals with dementia and may
reduce carers' burden.
Heyn et al carried out meta-analysis of exercise in
dementia and reported data on 30 trials of exercise [16].
The authors reported on trials that included strength,
cardiovascular or flexibility regimes; and analysed for
functional, cognitive or behavioural outcomes. A signifi-
cant positive effect of exercise on behavioural outcomes
was reported (Effect Size = 0.54; 95% Confidence Interval
= 0.36-.72). However these trials do not provide a full pic-
ture of the effectiveness of exercise on BPSD for a num-
ber of reasons. There was considerable heterogeneity in
terms of the interventions, and exercise was often com-
bined with other behavioural interventions. Thus, it is
difficult to isolate the impact that exercise has had on
behavioural outcomes. Some regimes were quite complex
and require a high degree of physical fitness that would
preclude many older adults with complex physical prob-
lems and moderate or profound dementia from perform-
ing them. Moreover, they were potentially unsustainable
without the support of trained therapists. Finally, the rel-
atively high cost of delivery and specialist input required
may prevent the interventions being used more widely.
Most trials included in the analysis were relatively small,
with only two of the eight studies that reported effects on
behaviours having samples in excess of 100 participants.
W e  h a v e  d e s i g n e d  a  s t u d y  t h a t  a i m s  t o  e v a l u a t e  t h e
effectiveness of exercise as a therapy for behavioural and
psychological symptoms of dementia. This will be a prag-
matic randomised trial conducted in a community cohort
in the UK nested within a larger programme of research.
The overarching programme investigates the impact of
various psychosocial interventions for people with
dementia, those who care for them and professionals that
support them (Evidence Based Interventions in Demen-
tia-EVIDEM). This has been a challenging design pro-
cess, which has seen the project team - supported by an
independent steering group - attempt to strike a balance
between achieving a feasible and sustainable interven-
tion, which could be widely adopted in the target popula-
tion while maintaining scientific rigour in its evaluation.
In the following, we describe the resultant and final
methodology and discuss the benefits & limitations to
our approach.
Study hypothesis
A programme of tailored incremental exercise (through
walking) improves the symptoms and outcome of Behav-
ioural and Psychological Symptoms of Dementia
Methods/Study Design
This trial has been granted ethical approval by the Outer
North East London Research Ethics Committee, REC ref-
erence number: 09/H0701/67.
We will undertake a pragmatic, randomised, controlled,
single-blind, parallel-group trial. Community-dwelling
individuals with a diagnosis of dementia or suspected
dementia who also have a carer willing and able to be a
co-participant in the exercise regime will be recruited to
this evaluation.
Participants will be randomly allocated to one of two
arms: the treatment arm, which includes receipt of an
individually tailored regime of walking (the intervention;
exercise therapy-ET) in addition to treatment as usual
(TAU) or the control arm which receives treatment as
usual only (see Figure 1). Treatment as usual may include
home care, attendance at day care facilities, visits by
health professionals, receipt of medication, respite care
etc.
Both the treatment and control arms will be re-assessed
for all outcomes at weeks 6 and 12. Further telephone
contact will occur at 26 weeks to assess adverse events,
mortality, change in domiciliary status and adherence to
exercise regime. The randomisation ratio for the two
groups will be 1:1 (ET:TAU). An Independent randomisa-
tion officer will use a computer algorithm to perform the
randomisation centrally after the initial interview, and
will communicate the results to the participants, the GP
and to the exercise therapist; but not to those collecting
research data.
Primary Objective
To determine the effectiveness of physical exercise deliv-
ered through a programme of incremental walking for
treating behavioural and psychological symptoms of
dementia (as defined by Neuropsychiatric Inventory
scores) compared with treatment as usual (TAU).Cerga-Pashoja et al. Trials 2010, 11:53
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Secondary Objectives
To determine the effect of exercise on 1) the quality of life
o f  p e o p l e  w i t h  d e m e n t i a ;  2 )  p s y c h o t r o p i c  m e d i c a t i o n
usage; 3) move to a residential care facility; 4) mortality
levels; 5) caregivers' perceived level of burden. We will
also carry out an economic evaluation of the intervention
and qualitatively explore participants' views about the
intervention and barriers to treatment.
Recruitment
The selection criteria for participation in the Evidem-E
trial are outlined in Table 1 (Table 1). Participants with a
clinical diagnosis of dementia or 'suspected dementia'
with at least one significant BPSD symptom defined by
the Neuropsychiatric Inventory (NPI)[17] (excluding the
domains of delusions and hallucinations) will be eligible
for the trial. Diagnosis of dementia will be confirmed in
accordance with ICD-10 Diagnostic Criteria for Research
(DCR-10). A risk assessment will be performed to assess
the suitability of participants for the intervention at base-
line. This assessment will include measurement for risk of
falls through the Falls Risk Assessment Tool (FRAT) [18]
and Timed Unsupported Steady Standing (TUSS) [19].
Individuals with dementia known to the General Prac-
titioner or secondary care will be identified and sus-
pected new cases will be assessed to confirm diagnosis.
Regular reminders about the study will be sent to partici-
pating practices and secondary care teams within the net-
work catchment's area. A central register of all referrals
will be maintained.
There are four potential sources of recruitment:
• The locally adopted Dementia Registry (DemReg) of
people with dementia interested in participating in
research.
• GP practices that are affiliated to the EVIDEM
Research Group
• Memory assessment services and community men-
tal health services (e.g. Admiral Nurses) recruited via
CNWL NHS Foundation Trust
• Self referral
Interventions
Physical exercise will be delivered as an individually tai-
lored regime of walking designed to become progres-
sively intensive and last between 20-30 minutes. This will
be facilitated by a qualified exercise therapist and deliv-
ered to participants in the treatment arm of the trial (Fig-
ure 2) in the area around their own home. The exercise
therapist will facilitate physical exercise in the partici-
pant-carer dyad with the expectation that the dyad will
perform the exercise regime regularly and independently
of the therapist at least 5 times per week. The interven-
tion has been structured so that the therapist adopts a
phased withdrawal approach utilising both face-to-face
contacts and telephone support contacts.
The dyad on the intervention group will also be asked
to complete a visual analogue scale called the Rating of
Perceived Exertion (RPE) [20]. Perceived exertion is
based on the physical sensations a person experiences
during physical activity, including increased heart rate,
increased respiration or breathing rate, increased sweat-
i n g ,  a n d  m u s c l e  f a t i g u e .  A l t h o u g h  t h i s  i s  a  s u b j e c t i v e
measure, a person's exertion rating may provide a fairly
Figure 1 Randomisation of participants and data collection.Cerga-Pashoja et al. Trials 2010, 11:53
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good estimate of the actual heart rate during physical
activity (Borg, 1998). The exercise therapist will not only
assess the RPE but train participants to evaluate them-
selves and will encourage the dyad to extend walking
exercise to 60-70% of RPE.
The participants in the treatment arm will be asked to
record their daily activities and RPE throughout the 12
weeks of their participation using a diary designed to
meet the specification of this study.
Outcome Assessments
Assessments will be conducted according to Figure 1.
Participants will be visited in either their own homes, or a
mutually acceptable convenient location (e.g. GP's clinic),
by a trained research worker (RW) masked to arm alloca-
tion.
The primary outcome measure will be changes to
behavioural and psychological symptoms measured by
the Neuropsychiatric Inventory (NPI) at baseline as well
as 6 and 12 weeks of participation.
Secondary outcome measures will be changes to: par-
ticipants' mental health (GHQ)[21], participants' quality
of life (DemQOL-Proxy)[22], and caregivers' burden of
caring (short ZBI) [23]. The secondary outcomes will also
be measured at baseline, 6 and 12 weeks into the trial.
Participants' level of physical activity and compliance
with the intervention will be measured through daily dia-
ries, Rate of Perceived Exertion (RPE), blood pressure and
heart rate monitoring. Diaries will also provide qualita-
tive information in regards to participants' views about
the intervention.
We will also carry out an Economic Evaluation through
the Client Service Receipt Inventory [24], which will be
administered at baseline and 12 weeks into the trial.
Domicile and mortality change will be measured at fol-
low-up, 26 weeks into the trial via a structured telephone
interview.
The exercise programme will be initiated and super-
vised by the Exercise Therapist. Baseline and subsequent
evaluations will be undertaken by RW. An independent
researcher (IR) will collect the primary outcome data
(NPI) at weeks 6 and 12, which will be completed by tele-
phone with the aim of minimising the risk of un-blinding
group allocation to research workers.
Sample size
Based on anticipated between-group absolute risk differ-
ence of 30% in number of people with BPSD symptoms
measured by the NPI, a sample size of 146 participants
will give 90% power to detect this difference with 95%
confidence. This calculation includes a 20% attrition esti-
mate. The sample size calculations have been described
in Table 2.
(calculated by http://www.stat.ubc.ca/~rollin/stats/
ssize/b2.html)
Statistical Methods
Baseline demographic and outcome data will be com-
pared between the two randomisation groups. Categori-
c a l  d a t a  w i l l  b e  a n a l y s e d  u s i n g  t h e  c h i - s q u a r e  t e s t .
Continuous data will be analysed using the t-test or if the
data is found to be non-normally distributed, we will use
the Wilcoxon Rank-Sum test.
Outcomes at 6 and 12 weeks will be compared between
randomisation groups using analysis of co-variance
(ANCOVA) for continuous data. The relevant baseline
scores will be included as the co-variate in order to adjust
for any potential baseline differences in the respective
outcome. Categorical outcomes will be compared using
the chi-square test.
All data will be analysed on an intention-to-treat basis,
where appropriate imputation of missing data will be
implemented. Under the assumption that data are miss-
ing at random multiple imputation will be used.
All analyses will be completed using the statistics pack-
age STATA.
Table 1: Selection criteria for inclusion/exclusion from the 
Evidem-E trial
Inclusion criteria Exclusion criteria
Diagnosis of:
a. Dementia in primary or 
secondary care OR
b. Suspected dementia 
confirmed by the researcher 
to ensure the DCR-10 criteria 
are met;
Presence of a carer 
(professional, friend or family 
member, who does not 
necessarily have to live with 
the participant);
Presence of BPSD measured 
through NPI. [NPI score in any 
one sub-set (except only 
hallucination or delusion) 
more than or equal to 2 in 
severity and more than or 
equal to 2 in frequency];
Consent of participant, or in 
the case of an individual who 
is not capable of giving 
informed consent, the assent 
of the participant with 
agreement of carer; Consent 
of carer.
Cardio-respiratory condition, 
neurological or musculo-
skeletal condition of a degree 
that prevents participation to 
even the modified exercise 
regime unsafe or not 
possible.
Three or more falls in the 
previous year ("frequent 
fallers") assessed by FRAT or 
high falls risk defined by 
TUSS;
Uncontrolled medical 
problems, which the GP 
considers would exclude 
participants from 
undertaking the exercise 
programme; for example, 
acute systemic illness' such 
as pneumonia, poorly 
controlled angina, acute 
rheumatoid arthritis, 
unstable or acute heart 
failure;
Sensory impairment to an 
extent that prevents dyad 
facilitated exercise;
Participant or carer dissent to 
engage in the exercise 
programme.Cerga-Pashoja et al. Trials 2010, 11:53
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Discussion
Behavioural and psychological symptoms are an intrinsic
feature of dementia that are often treated with drugs such
as antipsychotics, which are potentially unsafe to use in
this population. Alternative treatments for BPSD are
required but there is a dearth of research in the area. We
have tried to design a trial of exercise as therapy for
BPSD. Designing such a trial provides challenges that
drugs trials do not, such as: defining the treatment, main-
taining blinding, defining clear measurable outcomes and
ensuring the intervention is feasible and sustainable.
Exercise provides a promising intervention for BPSD,
but further work is needed. Previous studies have
reported the use of relatively complex exercise regimes
including aerobic, strength, flexibility and balance train-
ing [25,26]. Most ageing individuals suffer from physical
conditions such as cardio-respiratory illness, arthritis,
and sensory and mobility impairments. It is important,
therefore, that exercise therapy for this patient popula-
tion is sensitive to this. Our study group and the indepen-
dent Steering Group, which monitors and advises us,
agreed that 'walking' is a feasible, sustainable and cost
effective way of exercising. Walking is a simple way of
exercising which enjoys all the benefits of more complex
exercises but with the advantage of being sustained inde-
pendently even by individuals with moderate to severe
dementia and other physical conditions.
Careful consideration was taken in regards to blinding
the researcher to the allocation status of the participants.
The single blind design leaves us vulnerable to unmasking
group allocation during the interaction between
researcher and participant during visits. This everyday
conversation is essential to building a rapport with partic-
ipants and ensuring they feel comfortable in participat-
ing. All study personnel including researchers and
therapists will repeatedly remind participants of the
importance of not disclosing their group allocation. How-
ever, the risk will remain, and so we decided to include a
second 'independent' researcher whom would collect our
primary outcome data (NPI) at 6 and 12 weeks. The
premise for this approach is that this researcher can take
a less 'personal' tone and thus minimize the risk of con-
Figure 2 Intervention schedule.
Table 2: Power calculations
Control Intervention Difference N (including compensation 
for 20% attrition)
0.8 0.4 0.4 70 (88)
0.8 0.5 0.3 116 (145)
0.8 0.6 0.2 238 (298)Cerga-Pashoja et al. Trials 2010, 11:53
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versation with the dyad that might un-blind group alloca-
tion. However, there remains a risk that the dyad will
divulge information about the group they have been allo-
cated to. Therefore the efficacy of blinding will be
assessed at each time point, by personnel collecting data
who will record which arm they believe each dyad is ran-
domised to.
Separating the effect of psychosocial contact (from the
exercise therapist) from the exercise intervention has
proved to be the biggest challenge in our study. We
decided to address this problem by introducing two peri-
ods during the intervention: 1-6 weeks whereby the par-
ticipants in the intervention group will be trained and
supported by an exercise therapist and 6-12 weeks when
participants will receive absolutely no contact with the
therapist. This stage will also help to assess the interven-
tion's feasibility and sustainability in a community popu-
lation. The symptoms of BPSD tend to be relatively stable
over short time periods (i.e. months) so the two windows
provided by this method should detect responses influ-
enced purely because of exercise and not by any residual
benefits of interaction with the therapist. Although we
have tried to control for contacts between participants
and the exercise therapist, we could not control for the
social contact between the person with dementia and
their carer. Dyadic walking may encourage not just physi-
cal activity but psychosocial support from the carer as
well.
In terms of outcomes, we are using measures that are
validated and widely used in research with individuals
with dementia. We also gave considerable thought to the
issue of measuring physical activity. Particular consider-
ation was given to the use of equipment by the partici-
pants to record their individual activities e.g. Global
Positioning System receivers and pedometers. The fol-
lowing issues were identified:
- Measurement accuracy and information bias (partici-
pants are likely to forget to wear their equipment or they
may continue to wear equipment during non-activity
time);
- Practicality and intrusion (wearing equipment for 12
weeks on daily basis can be intrusive and this may affect
participation in the study and may give rise differential
attrition);
- Methodological problems (introducing a self adminis-
tered assessment of physical activity within the control
group could constitute an intervention in its own right.
There is potential for this to promote increased levels of
physical activity within the control group and thus reduce
the detectable effect size).
Therefore, we agreed to evaluate participants' level of
physical activity through measurements of the partici-
pants' self reported Rate of Perceived Exertion (exercise
group only). A proxy measure of fitness will be utilised to
assess for compliance with intervention. Heart rate at rest
will be assessed at the beginning, middle and end of the
trial for all participants. We expect that should partici-
pants adhere to the prescribed exercise regime, their fit-
ness will improve and ergo their heart rate at rest. We
hypothesise that with such an increase in activity we may
observe a reduction of BPSD. However we recognise that
detecting such changes in cardiovascular health may be
overambitious.
Assessing physical activity with minimum intrusion to
study participants is challenging and we are relying on
participants' self reports through daily dairies. Self-report
is prone to information bias, especially when participants
are not blinded to their group allocation. We may also
encounter a significant Hawthorn effect whereby partici-
pation in the study and study hypothesis in particular
may affect the behaviour of study participants. Thus, par-
ticipants in the control group who believe they may bene-
fit from regular exercise might increase their physical
activity during the study period, which in turn may
reduce any detectable effect due to the intervention.
Antipsychotic drugs, as discussed above, provide lim-
it ed e ffica cy in  t r ea t ing BPS D as we l l as  ha ving esta b-
lished safety concerns. Exercise, on the other hand, may
be effective but could also be associated with unknown
risks. At present we can not discern whether the uncon-
firmed risk of the exercise is more substantial than the
demonstrated risk of drugs. However, we have attempted
to develop a design with robust risk event detection to
mitigate this.
Designing the Evidem-E trial has proven to be very
challenging but we have attempted to overcome the chal-
lenges without compromising scientific rigour or study
feasibility. This trial is in accordance with the UK govern-
ment's action plan to tackle the over-prescribing of antip-
sychotic drugs to people with dementia.
If this trial is successful, its findings may be applicable
to a wide base of people diagnosed with dementia with
minimal costs.
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